Skip Navigation

Close and don't show again.

Your browser is out of date.

You may not get the full experience here on National Journal.

Please upgrade your browser to any of the following supported browsers:

Pfizer’s Third-Quarter Profit Falls Pfizer’s Third-Quarter Profit Falls

This ad will end in seconds
Close X

Want access to this content? Learn More »

Forget Your Password?

Don't have an account? Register »

Reveal Navigation


Pfizer’s Third-Quarter Profit Falls

The drug company faces lower profits as generic drugs increase competition.



The largest U.S. drugmaker's profit dropped 19 percent in the third quarter, due to increased competition for generic drugs, The New York Times reports.

The company's net income fell to $2.59 billion, or 39 cents a share, from $3.21 billion, or 43 cents a share, the year before.


Like many drug companies, Pfizer is feeling the impact of cheaper generic versions of drugs cutting into sales, with their older drugs no longer protected by patents.

Despite the decrease, Reuters presented the earnings as better than expected, citing the sale of its oncology drugs—which jumped 24 percent to $407 million—as a bright sport in the report. 

comments powered by Disqus